The induction of atherogenic dyslipidaemia in poloxamer 407-treated mice is not mediated through PPARα

Journal of Pharmacy and Pharmacology

Volumn 60, Issue 6, 2008, Pages 753-759

  Johnston, Thomas P ^a   Waxman, David J ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; POLOXAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DYSLIPIDEMIA; LIPID BLOOD LEVEL; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CERCOPITHECUS AETHIOPS; CHOLESTEROL; COS CELLS; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POLOXAMER; PPAR ALPHA; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS);

EID: 43949128062     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.60.6.0011     Document Type: Article

References (33)

1. Allain, C. A., Poor, L. S., Chan, C. S., Richmond, W., Fu, P. C. (1974) Enzymatic determination of total serum cholesterol. Clin. Chem. 20: 470-476
2. Bachorik, P. S., Albers, J. J. (1986) Precipitation methods for quantitation of lipoproteins. Methods Enzymol. 129: 78-100
3. Brocks, D. R., Ala, S., Aliabadi, H. M. (2006) The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat. Biopharm. Drug Dispos. 27: 7-16
4. Bucolo, G., David, H. (1973) Quantitative determination of serum triglycerides by the use of enzymes. Clin. Chem. 19: 476-479
5. Chang, T. K., Waxman, D. J. (2005) Pregnane X receptor-mediated transcription. Methods Enzymol. 400: 588-598
6. Chinetti, G., Fruchart, J. C., Staels, B. (2000a) Peroxisome proliferators-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 49: 497-505
7. Chinetti, G., Gbaguidi, G. F., Griglio, S., Mallat, Z., Antonucci, M., Poulain, P., Chapman, J., Fruchart, J. C., Tedgui, A., Najib-Fruchart, J., Staels, B. (2000b) CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activations of peroxisome proliferator-activated receptors. Circulation 101: 2411-2417
8. Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Pineda, T. I., Tessier, E., Minnich, A., Jaye, M., Duverger, N., Brewer, B. H., Fruchart, J. C., Clavey, V., Staels, B. (2001) PPARα and PPARγ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7: 53-58
9. Chinetti, G., Lestavel, S., Fruchart, J. C., Clavey, V., Staels, B. (2003) Peroxisome proliferator-activated receptor α reduces cholesterol esterification in macrophages. Circ. Res. 92: 212-217
10. Dansky, H. M., Charlton, S. A., Sikes, J. L., Heath, S. C., Simantov, R., Levin, L. F., Shu, P., Moore, K. J., Breslow, J. L., Smith, J. D. (1999) Genetic background determines the extent of atherosclerosis in apoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19: 1960-1968
11. Ducz, H., Chao, Y. S., Hernandez, M., Torpier, G., Poulain, P., Mundt, S., Mallat, Z., Teissier, E., Burton, C. A., Tedgui, A., Fruchart, J. C., Fievet, C., Wright, S. D., Staels, B. (2002) Reduction of atherosclerosis by the peroxisome proliferator-activated receptor α agonist fenofibrate in mice. J. Biol. Chem. 277: 48051-48057
12. Duez, H., Lefebvre, B., Poulain, P., Torra, I. P., Percevault, F., Luc, G., Peters, J. M., Gonzalez, F. J., Gineste, R., Helleboid, S., Dzavik, V., Fruchart, J. C., Fievet, C., Lefebvre, P., Staels, B. (2005) Regulation of human apoAI by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler. Thromb. Vasc. Biol. 25: 585-591
13. Fu, T., Kashireddy, P., Borensztajn, J. (2003) The peroxisome- proliferator-activated receptor α agonist ciprofibrate severely aggravates hypercholesterolemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. Biochem. J. 373:941-947
14. Johnston, T. P. (2004) The P-407-induced murine model of dose-controlled hyperlipidemia and atherosclerosis: a review of findings to date. J. Cardiovasc. Pharmacol. 43: 595-606
15. Johnston, T. P., Palmer, W. K. (1997) Effect of poloxamer 407 on the activity of microsomal 3-hydroxy-3-methylglutaryl CoA reductase in rats. J. Cardiovasc. Pharmacol. 29: 580-585
16. Johnston, T. P., Zhou, X. (2007) Oxidation of low-density lipoprotein cholesterol following administration of poloxamer 407 to mice results from an indirect effect. J. Cardiovasc. Pharmacol. 49: 246-252
17. Johnston, T. P., Baker, J. C., Jamal, A. S., Hall, D. D., Emeson, E. E., Palmer, W. K. (1999) Potential downregulation of HMG-CoA reductase after prolonged administration of P-407 in C57BL/6 mice. J. Cardiovasc. Pharmacol. 34: 831-842
18. Johnston, T. P., Jaye, M., Webb, C. L., Krawiec, J. A., Alom-Ruiz, S. P., Sachs-Barrable, K., Wasan, K. M. (2006) Poloxamer 407 (P-407)-mediated reduction in the gene expression of ATP-binding-cassette transporter A1 may contribute to increased cholesterol in peripheral tissues of P-407-treated rats. Eur. J. Pharmacol. 536: 232-240
19. Joyce, C. W., Amar, M. J. A., Lambert, G., Vaisman, B. L., Paigen, B., Najib-Fruchart, J., Hoyt, R. F., Neufeld, E. D., Remaley, A. T., Fredrickson, D. S., Brewer, H. B., Santamarina-Fojo, S. (2002) The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc. Natl Acad. Sci. USA 99: 407-412
20. Leon, C., Wasan, K. M., Sachs-Barrable, K., Johnston, T. P. (2006) Acute P-407 administration to mice causes hypercholesterolemia by inducing cholesterolgenesis and down-regulating low-density lipoprotein receptor expression. Pharm. Res. 23: 1597-1607
21. Maloney, E. K., Waxman, D. J. (1999) trans-activation of PPARα and PPARγ by structurally diverse environmental chemicals. Toxicol. Appl. Pharmacol. 161: 209-218
22. Marx, N., Duez, H., Fruchart, J. C., Staels, B. (2004) Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 94: 1168-1178
23. Millar, J. S., Cromley, D. A., McCoy, M. G., Rader, D. J., Billheimer, J. T. (2005) Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. J. Lipid Res. 46: 2023-2028
24. Ngoc, V. D., Chopin-Delannoy, S., Gervois, P., Bonnelye, E., Martin, G., Fruchart, J., Laudet, V., Staels, B. (1998) The nuclear receptors peroxisome proliferator-activated receptor α and Reverbα mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J. Biol. Chem. 273: 25713-25720
25. Palmer, W. K., Emeson, E. E., Johnston, T. P. (1998) Poloxamer 407-induced atherogenesis in the C57BL/6 mouse. Atherosclerosis 136: 115-123
26. Peters, J. M., Zhou, Y. C., Ram, P. A., Lee, S. S., Gonzalez, F. J., Waxman, D. J. (1996) Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate. Mol. Pharmacol. 50: 67-74
27. Peters, J. M., Hennuyer, N., Staels, B., Fruchart, J. C., Fievet, C., Gonzalez, F. J., Auwerx, J. (1997) Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J. Biol. Chem. 272: 27307-27312
28. Pineda, T. I., Gervois, P., Staels, B. (1999) Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis, and aging. Curr. Opin. Lipidol. 10: 151-159
29. Schoonjans, K., Staels, B., Auwerx, J. (1996) The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta 1302: 93-109
30. Shipley, J. M., Waxman, D. J. (2004) Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b. Toxicol. Appl. Pharmacol. 199: 275-284
31. Shipley, J. M., Hurst, C. H., Tanaka, S. S., DeRoos, F. L., Butenhoff, J. L., Seacat, A. M., Waxman, D. J. (2004) trans-activation of PPARα and induction of PPARα target genes by perfluorooctane-based chemicals. Toxicol. Sci. 80: 151-160
32. Staels, B., van Tol, A., Andreu, T., Auwerx, J. (1992) Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler. Thromb. 12: 286-294
33. Wahrle, S. E., Jiang, H., Parsadanian, M., Legleiter, J., Han, X., Fryer, J. D., Kowalewski, T., Holtzman, D. M. (2004) ABCA1 is required for normal central nervous system apoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem. 279: 40987-40993